Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>

Ovarian Cancer Videos

Dr. Liu on PARP Inhibitors in Recurrent Ovarian Cancer
Dr. Liu on PARP Inhibitors in Recurrent Ovarian Cancer
Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in patients with recurrent ovarian cancer.
Onclive TV   >   
Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses patient eligibility for neoadjuvant chemotherapy in advanced ovarian cancer.
Onclive TV   >   
Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer
Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer
David Cibula, MD, a gynecologic oncologist at the Gynaecologic Center of Charles University, discusses a trial that examined the addition of dendritic cell-based immunotherapy to chemotherapy in patients with relapsed ovarian cancer.
Onclive TV   >   
Dr. Essel on Repeat Use of PARP Inhibitors in Ovarian Cancer
Dr. Essel on Repeat Use of PARP Inhibitors in Ovarian Cancer
Kathleen G. Essel, MD, gynecologic oncology fellow, Stephenson Cancer Center, University of Oklahoma, discusses repeat exposure to PARP inhibitors in the treatment of patients with ovarian cancer.
 
Onclive TV   >   
Coming Soon: Shifting Paradigms in Ovarian Cancer
Coming Soon: Shifting Paradigms in Ovarian Cancer
Bradley J. Monk, MD, shares news of an upcoming OncLive Peer Exchange® on ovarian cancer to follow new data from the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
Peer Exchange   >   Shifting Paradigms in Ovarian Cancer
Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer
Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer
Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of rucaparib in the treatment of patients with ovarian cancer.
Onclive TV   >   
Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer
Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.
Onclive TV   >   
Dr. Landen Discusses p53 Mutations in Ovarian Cancer
Dr. Landen Discusses p53 Mutations in Ovarian Cancer
Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the role of p53 mutations in patients with ovarian cancer.
Onclive TV   >   
Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer
Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer
Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.
Conference Coverage   >   2019 SGO Annual Meeting
Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer
Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer
Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.
Conference Coverage   >   2019 SGO Annual Meeting
Next Page >>
Publication Bottom Border
Border Publication
 
x